Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Proof of Concept Study of Vagus Nerve Stimulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03689621
Recruitment Status : Completed
First Posted : September 28, 2018
Last Update Posted : April 17, 2019
Sponsor:
Collaborator:
Foundation for Prader-Willi Research
Information provided by (Responsible Party):
Jessica Beresford-Webb, University of Cambridge

Brief Summary:

The investigator's recent pilot study of vagus nerve stimulation (VNS) from a surgically implanted medical device to control the excess eating behaviour characteristic of Prader-Willi Syndrome (PWS) found that it was safe and acceptable. In addition, there were unanticipated marked improvements in rates of problem behaviours, such as emotional disturbances and verbal and physical outbursts. These observations indicated the need for a trial specifically focusing on the effects of VNS on problem behaviour and also that the use of VNS might be extended to include people with other neurodevelopmental disorders, such as autism spectrum conditions (ASC). The primary aims of this study are: a) to investigate whether VNS, now given by an external medical device, is associated with a significant reduction in the number and severity of maladaptive behaviours in adults with PWS; and b) to undertake a pilot study that includes others with a different neurodevelopmental syndrome who have histories of similar behaviours.

The study will be a single case cross-over design with 4 to 6 months baseline phase and a similar period of active treatment. The study cannot be blind as the stimulation is apparent but the participants will wear the device initially for four hours a day, at times convenient to them, with it switched off in the baseline phase and activated, according to standard protocols, in the treatment phase. Six adults with PWS and six with a different neurodevelopmental disorder with histories of significant problem behaviours will be included initially, with a view to extending if the analysis indicates a likely effect. Behaviours will be operationally defined and measured over time using participant and informant diaries with additional secondary outcome measures. Before and during the treatment phases autonomic nervous system and brain biomarkers will be assessed using ambulatory monitoring of heart rate variability and fMRI brain scans.


Condition or disease Intervention/treatment Phase
Transcutaneous Vagal Nerve Stimulation (tVNS) Prader-Willi Syndrome Device: Transcutaneous vagus nerve stimulation (tVNS) Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 9 participants
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Proof of Concept Study of Vagus Nerve Stimulation Using an External Device for the Treatment of Behaviour Problems in People With Neurodevelopmental Disorders, Specifically Prader Willi Syndrome
Actual Study Start Date : January 1, 2016
Actual Primary Completion Date : December 31, 2018
Actual Study Completion Date : December 31, 2018

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Transcutaneous vagal nerve stimulation (tVNS)
tVNS administered for 4 hours each day and behaviour is recorded.
Device: Transcutaneous vagus nerve stimulation (tVNS)
Placebo Comparator: Baseline
tVNS worn but not switched on whilst collecting behavioural data.
Device: Transcutaneous vagus nerve stimulation (tVNS)



Primary Outcome Measures :
  1. The number of operationally defined outbursts [ Time Frame: 15-17 months ]
    Measured using participant and informant diaries.


Secondary Outcome Measures :
  1. The Challenging Behaviour Checklist [ Time Frame: 15-17 months ]
    Scores on rating scale, repeated over time. Score range 50-55. higher score indicates more severe behaviour.

  2. Repetitive Behaviour Questionnaire [ Time Frame: 15-17 months ]
    Scores on rating scale, repeated over time. Total scores range between 20-60. The higher toe score the worse behaviours are.

  3. Life Experiences Checklist. [ Time Frame: 15-17 months ]
    Intended to gather information about the potentially traumatic experiences a person has experienced. There is no formal scoring protocol or interpretation per se, other than identifying whether a person has experienced one or more of the events listed. Respondents indicate varying levels of exposure to each type of potentially traumatic event included on a 6-point nominal scale, and respondents may endorse multiple levels of exposure to the same trauma type.

  4. fMRI at resting and on-task [ Time Frame: 15-17 months ]
    FMRI data will be analysed using both 1st and 2nd level general linear model (GLM) analyses to compare within cases and across time points. Network analyses of functional connectivity may also be appropriate

  5. Participants response to challenge [ Time Frame: 15-17 months ]
    Using methodology developed by Prof Oliver, filmed and subsequently rated blind for emotional and behavioural changes.

  6. Semi-structured interviews [ Time Frame: 15-17 months ]
    With participants and carers to probe about any observed subtle changes in behaviour. Analysed thematically.

  7. Attention shifting ability [ Time Frame: 15-17 months ]
    Tested via go-no-go task developed for people with PWS by Woodcock et al (2009). Reaction times analysed.

  8. Salival cortisol measures [ Time Frame: 15-17 months ]
    recorded across the course of four separate days during the course of study (at waking, 30 minutes post-waking, 45 minutes post-waking, 1 hour post-waking and then four more times throughout the day at approximately +3h, +6h, +9h and +14h after waking).

  9. Vocal prosody [ Time Frame: 15-17 months ]
    Two voice recordings of the participant talking will be collected on each of these occasions. Each recording will be at least 20 seconds long, with the participant asked to talk about a positive experience (e.g. favourite birthday, best friend etc.) in one, a less positive time (e.g. a time when he/she was disappointed or sad) in the other. These will be analysed for changes in vocal prosody with t-VNS.

  10. Heart Rate Variability [ Time Frame: 15-17 months ]
    derived from ECG and respiration measured using an Intelesens (Belfast) 3-axis 'Zensor' wearable monitor. For each participant ECG recording will take place in 24-hour blocks. HRV will be determined from R-R intervals as root mean of squared successive differences and average HRV will be determined for each participant for brief (15 minutes) and prolonged (24 hours) periods.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or female aged over 18 years of age.
  • Genetically and clinically determined diagnosis of PWS or meeting clinical or the presence of another neurodevelopmental syndrome such as an autistic spectrum condition.
  • History of problem behaviours of, on average, at least one significant informant-reported episode each week.
  • Capacity to consent.
  • Able to commit to the study duration and to attend assessments in Cambridge.

Exclusion Criteria:

  • Meet exclusion criteria for MRI scanning and/or unable to tolerate MRI environment.
  • Serious co-morbid physical or psychiatric disorder which would disrupt ability to comply with study demands (e.g. a history of serious bipolar disorder; sleep apnoea not well-controlled with CPAP; insulin dependent diabetes).
  • Current or past history of neurological disorders or trauma, including epilepsy, and head injury.
  • Currently or recently (within 12 months) participating in a clinical trial of an investigational medicinal product (CTIMP) or another medical device.
  • Lacking the capacity to consent.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03689621


Sponsors and Collaborators
Jessica Beresford-Webb
Foundation for Prader-Willi Research
Investigators
Layout table for investigator information
Principal Investigator: Tony Holland, Prof. University of Cambridge
  Study Documents (Full-Text)

Documents provided by Jessica Beresford-Webb, University of Cambridge:
Layout table for additonal information
Responsible Party: Jessica Beresford-Webb, Research Assistant, University of Cambridge
ClinicalTrials.gov Identifier: NCT03689621    
Other Study ID Numbers: 15/EE/0450
First Posted: September 28, 2018    Key Record Dates
Last Update Posted: April 17, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Prader-Willi Syndrome
Syndrome
Disease
Pathologic Processes
Intellectual Disability
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Abnormalities, Multiple
Congenital Abnormalities
Chromosome Disorders
Genetic Diseases, Inborn
Obesity
Overnutrition
Nutrition Disorders